Skip to main content

Table 1 Demographics and baseline characteristics of study subjects, Study 1 (FTIH)

From: The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756) − a selective CXCR2 antagonist − in healthy adult subjects

  Cohorts 1 and 2 Cohorts 3 and 4 Cohort 5
Placebo RD danirixin 50 mg RD danirixin 200 mg RD Placebo SD danirixin 400 mg SD
Age, yrs mean (SD) 35 (13) 35 (8) 29 (10) 33 (14) 27 (5) 25 (4)
n, (% male) 30 (100 %) 8 (100 %) 10 (100 %) 10 (100 %) 5 (100 %) 10 (100 %)
Race, n (%)       
White 25 (83) 6 (75) 10 (100) 9 (90) 4 (80) 7 (70)
African-American 3 (10) 2 (25) 0 0 1 (20) 1 (10)
Asian 2 (6) 0 0 1(10) 0 2 (20)
BMI (kg/m2) mean (SD) 25 (2) 26 (3) 25 (2) 25 (3) 24 (4) 24 (2)